EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Folic Acid-Targeted Liposome-Based Nanoparticle Loaded with Sorafenib for Liver Cancer Therapy

Songyang Liu, Dan Yi iD, Rui Ma, Wei Zhang

International Journal of Nanomedicine · 2025

DOI: 10.2147/ijn.s489777 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2025. Verfasst von Songyang Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, 130061, People's Repub…. Hauptthemen laut MEDLINE: Folic Acid, Liposomes, Liver Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Sorafenib (SF) is a small molecule involved in tumor proliferation and angiogenesis. SF is inhibitor of several kinases, including RAF, VEGFR, and PDGFR. However the weak targeting ability of SF for liver tumor tissues is the major problem in clinical therapy. Therefore, a SF-loaded folic acid-targeted liposome drug delivery system was devised for targeting liver tumor therapy in this study.

Methods

Folic acid (FA), HSPC, DSPE-PEG2k, CHO, and SF were composed to prepare a folic acid-targeted SF-loaded liposome (LSF) drug delivery system. LSF and drug loading content was established through thin-film-hydration technique and HPLC, respectively. The particle size and stability of LSF were examined by dynamic light scattering (DLS). The inhibition effect of LSF was elucidated in vitro on liver cancer cells through cell cytotoxicity and apoptosis experiments. The tumor-inhibiting efficacy was measured on liver xenograft model.

Results

The drug loading content (DLC) of LSF was 3.6%. The diameter of LSF was 197.1±16.6 nm, and LSF was stable during 24 h. Liver cancer cells could be effectively inhibited by LSF in vitro. LSF could substantially induce apoptosis. Also, LSF could inhibit tumor growth effectively in vivo. LSF could reduce side effects of SF demonstrated by bio-safety tests.

Conclusion

LSF is a FA-targeted drug delivery system that could effectively inhibit the progression of liver cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Folic AcidLiposomesLiver NeoplasmsAntineoplastic AgentsNanoparticlesNiacinamidePhenylurea CompoundsSorafenibAnimalsHumansApoptosisMiceCell Line, TumorXenograft Model Antitumor AssaysMice, NudeParticle SizeMice, Inbred BALB CDrug Delivery SystemsMaleHep G2 Cells

Stichwörter der Autor:innen

folic acidliposomeliver cancersorafenibtargeting delivery

Substanzen

SorafenibFolic AcidLiposomesAntineoplastic AgentsNiacinamidePhenylurea Compounds

Autor:innen und Institutionen

  • Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, 130061, People's Republic of China.
  • Department of VascularSurgery Qiqihar first hospital, Qiqihar City, Heilongjiang Province, 161000, People's Republic of China.

ORCID-Profile: Dan Yi

Zitieren

APA

Liu, S., Yi, D., Ma, R., & Zhang, W. (2025). Folic Acid-Targeted Liposome-Based Nanoparticle Loaded with Sorafenib for Liver Cancer Therapy. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s489777

Vancouver

Liu S, Yi D, Ma R, Zhang W. Folic Acid-Targeted Liposome-Based Nanoparticle Loaded with Sorafenib for Liver Cancer Therapy. International Journal of Nanomedicine. 2025. doi:10.2147/ijn.s489777

BibTeX
@article{Liu2025,
  author = {Liu, Songyang and Yi, Dan and Ma, Rui and Zhang, Wei},
  title = {Folic Acid-Targeted Liposome-Based Nanoparticle Loaded with Sorafenib for Liver Cancer Therapy},
  journal = {International Journal of Nanomedicine},
  year = {2025},
  doi = {10.2147/ijn.s489777}
}
Kostenlos starten →